Background: Technical advances have allowed the delivery of a higher dose to the tumor volumes, while reducing the dose to nearby organs at risk. Laboratory and clinical evidence suggest that hypofractionation might raise the therapeutic effect. We report our outcomes of moderately hypofractionated schedules with volumetric modulated arc radiotherapy (VMAT) on biochemical failure (BCF) free survival and toxicities in patients with localized prostate cancer. Materials and Methods: Between 2013 and 2017, 58 patients were treated using the VMAT technique with daily image guided radiotherapy (IGRT). 3 (5.2%), 32 (55.2%), and 23 (39.7%) of patients had low, intermediate, or high risk disease, respectively. A prescription dose of 70 Gy in 2.5 Gy daily for 28 fractions was used. BCF-free survival was evaluated using 2005 Phoenix criteria and estimated using the Kaplan–Meier method. Radiotherapy-related toxicity was scored according to the Common Terminology Criteria for Adverse Events 4.0 criteria. Results: The median follow-up was 37.3 months (range 18.8-82.1). Overall 4 year BCF-free survival were 94.0%. For low-intermediate and high risk patients, the 4 year BCF-free survival were 100% and 83.3%, respectively (p=0.027). Pretreatment prostate-specific antigen (p=0.016) and Gleason score (p=0.007) were significant predictors of BCF-fee survival. The incidence of late grade 2 gastrointestinal and genitourinary toxicity was 8.6% and 13.8%, respectively. No grade 3 or greater toxicities were observed. Conclusions: Outcoms after moderately hypofractionated VMAT-IGRT were encouraging. Moderate hypofractionation was effective and safe for the treatment of localized prostate cancer.